2021
How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer?
Chagpar A, Lannin D, Mougalian S, Berger E, Gross C, Horowitz N, Sanft T, DiGiovanna M, Golshan M, Pusztai L. How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer? Journal Of Clinical Oncology 2021, 39: e18708-e18708. DOI: 10.1200/jco.2021.39.15_suppl.e18708.Peer-Reviewed Original ResearchUse of NTNeoadjuvant therapyEarly pandemic periodBreast cancerNon-metastatic breast cancerPractice settingsEarly pandemicFlatiron Health databaseNeoadjuvant endocrine therapyTechnology-enabled abstractionSame period one yearSimilar clinicopathologic featuresLongitudinal electronic health recordsPeriod one yearElectronic health recordsTNBC subsetEndocrine therapyPatient ageTN patientsClinicopathologic featuresContemporary cohortClinical stageCancer clinicCancer managementHigh risk
2020
The impact of pattern of tumor response and other post-treatment histologic features on local recurrence in patients treated with neoadjuvant chemotherapy and breast conservation.
Laws A, Pastorello R, Choi J, Kantor O, Grossmith S, Schnitt S, Golshan M, Mittendorf E, King T. The impact of pattern of tumor response and other post-treatment histologic features on local recurrence in patients treated with neoadjuvant chemotherapy and breast conservation. Journal Of Clinical Oncology 2020, 38: 581-581. DOI: 10.1200/jco.2020.38.15_suppl.581.Peer-Reviewed Original ResearchPathologic complete responseResidual invasive diseaseLocal recurrenceNeoadjuvant chemotherapyBreast-conserving surgeryResidual DCISTumor responseResidual diseaseInvasive diseaseBreast pathologic complete responseDetailed pathology reviewAdjuvant endocrine therapyPoor prognostic factorModern systemic therapyTreatment effectsNeoadjuvant trastuzumabRCB scoreEndocrine therapyFree survivalMulticentric diseaseBreast conservationComplete responseLymphovascular invasionMargin statusPrognostic factors
2013
Management of the axilla II
Dominici L, Golshan M. Management of the axilla II. 2013, 441-446. DOI: 10.1201/b13937-44.Peer-Reviewed Original ResearchSystemic therapyBreast cancerTumor biologyIndividual patient's tumor biologyAdjuvant treatment recommendationsPatient's tumor biologyAxillary lymph nodesWhole breast irradiationPatients breast cancerNovel chemotherapeutic agentsEndocrine therapyLocal therapyLymph nodesTreatment recommendationsAromatase inhibitorsRadiation therapyLocal controlTherapyChemotherapeutic agentsAccelerated formsSame periodMethods of evaluationCancerBreast